According to Orange Book, a regular report by Synergy Research Group, Petrovax Pharm has become one of the Top 5 companies by number of clinical trials started in Q2 2014 in the Russian pharmaceuticals market.
Since the beginning of 2014, Petrovax has initiated three new clinical trials: for Vitaoxymer, a large volume parenteral and detoxifier, Azoxiferon, intended for treating hepatitis C and B virus infections, and Longidaze, an enzyme-containing drug for the prevention and combination therapy of diseases associated with connective tissue hyperplasia.
Petrovax puts special emphasis on research and development and mobilises significant investment for the development of new high-demand drugs and their launch on domestic and international markets. The company has an in-house research centre engaged in developing innovative pharmaceuticals and new dosage forms, from molecule synthesis to drug registration. Currently, several innovative products are undergoing various development phases.
Clinical trials are an important stage of drug creation used for evaluating drug safety and efficacy. Clinical trials involve the leading research centres, contract research organisations and laboratories that have state-of-the-art equipment and highly qualified personnel. All clinical trials initiated by Petrovax are in strict compliance with international standards and GCP rules.
Synergy Research Group is a Russian contract research organisation with nationwide and CIS operations since 2002. In its report, Synergy Research Group says that in Q2 2014, a total of 194 permits were issued by the Russian Ministry of Health for all types of clinical trials, which is a 3% decline year-on-year. At the same time, the number of new international multicentre clinical trials has remained the same versus last year, standing at 81.